Sichuan Kelun Pharmaceutical Co Ltd
Sichuan Kelun Pharmaceutical Co., Ltd. researches, develops, produces, and sells infusion and non-infusion pharmaceutical products in China and internationally. It operates through Twinings, Botai, and Other Business segments. The company offers infusion products; oral medication and other dosage form; medical devices, such as infusion sets, sterile dispensing and injection syringes, vein detaine… Read more
Sichuan Kelun Pharmaceutical Co Ltd (002422) - Net Assets
Latest net assets as of September 2025: CN¥28.62 Billion CNY
Based on the latest financial reports, Sichuan Kelun Pharmaceutical Co Ltd (002422) has net assets worth CN¥28.62 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥40.10 Billion) and total liabilities (CN¥11.48 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥28.62 Billion |
| % of Total Assets | 71.37% |
| Annual Growth Rate | 23.99% |
| 5-Year Change | 90.94% |
| 10-Year Change | 139.51% |
| Growth Volatility | 79.74 |
Sichuan Kelun Pharmaceutical Co Ltd - Net Assets Trend (2007–2024)
This chart illustrates how Sichuan Kelun Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Sichuan Kelun Pharmaceutical Co Ltd (2007–2024)
The table below shows the annual net assets of Sichuan Kelun Pharmaceutical Co Ltd from 2007 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥26.74 Billion | +16.17% |
| 2023-12-31 | CN¥23.02 Billion | +36.28% |
| 2022-12-31 | CN¥16.89 Billion | +19.52% |
| 2021-12-31 | CN¥14.13 Billion | +0.90% |
| 2020-12-31 | CN¥14.00 Billion | +0.70% |
| 2019-12-31 | CN¥13.91 Billion | +7.27% |
| 2018-12-31 | CN¥12.96 Billion | +8.19% |
| 2017-12-31 | CN¥11.98 Billion | +4.50% |
| 2016-12-31 | CN¥11.47 Billion | +2.71% |
| 2015-12-31 | CN¥11.16 Billion | +1.76% |
| 2014-12-31 | CN¥10.97 Billion | +9.44% |
| 2013-12-31 | CN¥10.02 Billion | +10.59% |
| 2012-12-31 | CN¥9.06 Billion | +14.29% |
| 2011-12-31 | CN¥7.93 Billion | +12.47% |
| 2010-12-31 | CN¥7.05 Billion | +346.47% |
| 2009-12-31 | CN¥1.58 Billion | +32.70% |
| 2008-12-31 | CN¥1.19 Billion | +72.19% |
| 2007-12-31 | CN¥691.22 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Sichuan Kelun Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 2721.2% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥11.60 Billion | 51.61% |
| Common Stock | CN¥1.60 Billion | 7.12% |
| Other Components | CN¥9.28 Billion | 41.26% |
| Total Equity | CN¥22.48 Billion | 100.00% |
Sichuan Kelun Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of Sichuan Kelun Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Howden Joinery Group Plc
PINK:HWDJF
|
$5.09 Billion |
|
Protagonist Therapeutics Inc
NASDAQ:PTGX
|
$5.09 Billion |
|
Sonoco Products Company
NYSE:SON
|
$5.10 Billion |
|
Guangdong Haid Group Co Ltd
SHE:002311
|
$5.10 Billion |
|
Macerich Company
NYSE:MAC
|
$5.08 Billion |
|
Wex Inc
NYSE:WEX
|
$5.08 Billion |
|
Lotes Co Ltd
TW:3533
|
$5.08 Billion |
|
Home BancShares Inc
NYSE:HOMB
|
$5.07 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Sichuan Kelun Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 19,672,377,989 to 22,479,520,000, a change of 2,807,142,011 (14.3%).
- Net income of 2,935,892,000 contributed positively to equity growth.
- Dividend payments of 1,811,569,049 reduced retained earnings.
- Other comprehensive income decreased equity by 1,696,307,132.
- Other factors increased equity by 3,379,126,192.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥2.94 Billion | +13.06% |
| Dividends Paid | CN¥1.81 Billion | -8.06% |
| Other Comprehensive Income | CN¥-1.70 Billion | -7.55% |
| Other Changes | CN¥3.38 Billion | +15.03% |
| Total Change | CN¥- | 14.27% |
Book Value vs Market Value Analysis
This analysis compares Sichuan Kelun Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.41x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 51.57x to 2.41x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-12-31 | CN¥0.67 | CN¥34.34 | x |
| 2008-12-31 | CN¥1.10 | CN¥34.34 | x |
| 2009-12-31 | CN¥1.45 | CN¥34.34 | x |
| 2010-12-31 | CN¥5.43 | CN¥34.34 | x |
| 2011-12-31 | CN¥5.43 | CN¥34.34 | x |
| 2012-12-31 | CN¥6.12 | CN¥34.34 | x |
| 2013-12-31 | CN¥6.78 | CN¥34.34 | x |
| 2014-12-31 | CN¥7.50 | CN¥34.34 | x |
| 2015-12-31 | CN¥7.71 | CN¥34.34 | x |
| 2016-12-31 | CN¥7.95 | CN¥34.34 | x |
| 2017-12-31 | CN¥8.20 | CN¥34.34 | x |
| 2018-12-31 | CN¥8.94 | CN¥34.34 | x |
| 2019-12-31 | CN¥9.28 | CN¥34.34 | x |
| 2020-12-31 | CN¥9.44 | CN¥34.34 | x |
| 2021-12-31 | CN¥9.80 | CN¥34.34 | x |
| 2022-12-31 | CN¥10.60 | CN¥34.34 | x |
| 2023-12-31 | CN¥12.74 | CN¥34.34 | x |
| 2024-12-31 | CN¥14.24 | CN¥34.34 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Sichuan Kelun Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 13.06%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 13.46%
- • Asset Turnover: 0.58x
- • Equity Multiplier: 1.66x
- Recent ROE (13.06%) is above the historical average (12.48%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | 32.04% | 10.66% | 1.14x | 2.65x | CN¥148.78 Million |
| 2008 | 26.41% | 11.82% | 0.99x | 2.26x | CN¥192.55 Million |
| 2009 | 27.29% | 13.18% | 0.97x | 2.13x | CN¥271.04 Million |
| 2010 | 9.46% | 16.42% | 0.46x | 1.26x | CN¥-37.84 Million |
| 2011 | 12.33% | 18.77% | 0.49x | 1.34x | CN¥182.43 Million |
| 2012 | 12.35% | 18.48% | 0.39x | 1.70x | CN¥207.23 Million |
| 2013 | 11.06% | 15.80% | 0.38x | 1.84x | CN¥103.53 Million |
| 2014 | 9.33% | 12.49% | 0.38x | 1.97x | CN¥-72.05 Million |
| 2015 | 5.83% | 8.31% | 0.34x | 2.04x | CN¥-460.73 Million |
| 2016 | 5.16% | 6.83% | 0.37x | 2.07x | CN¥-548.38 Million |
| 2017 | 6.34% | 6.55% | 0.41x | 2.37x | CN¥-431.76 Million |
| 2018 | 9.50% | 7.42% | 0.56x | 2.30x | CN¥-63.40 Million |
| 2019 | 7.11% | 5.32% | 0.56x | 2.39x | CN¥-380.95 Million |
| 2020 | 6.14% | 5.04% | 0.51x | 2.37x | CN¥-520.53 Million |
| 2021 | 7.96% | 6.38% | 0.55x | 2.28x | CN¥-283.13 Million |
| 2022 | 10.83% | 8.96% | 0.56x | 2.17x | CN¥130.20 Million |
| 2023 | 12.49% | 11.45% | 0.59x | 1.85x | CN¥488.87 Million |
| 2024 | 13.06% | 13.46% | 0.58x | 1.66x | CN¥687.94 Million |
Industry Comparison
This section compares Sichuan Kelun Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $506,118,300
- Average return on equity (ROE) among peers: 3.81%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Sichuan Kelun Pharmaceutical Co Ltd (002422) | CN¥28.62 Billion | 32.04% | 0.40x | $5.09 Billion |
| Zhejiang Int'L Group Co Ltd (000411) | $130.09 Million | -53.07% | 2.31x | $194.13 Million |
| Zhejiang Zhenyuan Share Co Ltd (000705) | $34.35 Million | 19.93% | 2.59x | $306.72 Million |
| Hunan Jingfeng Pharmaceutical (000908) | $522.69 Million | 2.68% | 0.66x | $280.77 Million |
| Hubei Guangji Pharmaceutical Co Ltd (000952) | $531.76 Million | 1.61% | 0.66x | $225.65 Million |
| Zhejiang Haisen Pharmaceutical Co. Ltd. A (001367) | $469.03 Million | 22.94% | 0.21x | $163.86 Million |
| Yifan Xinfu Pharmaceutical Co Ltd (002019) | $79.43 Million | 32.82% | 0.66x | $932.68 Million |
| Guangdong Jiaying Pharmaceutical Co Ltd (002198) | $984.87 Million | 5.60% | 0.12x | $434.96 Million |
| Chongqing Lummy Pharmaceutical (300006) | $1.65 Billion | -9.38% | 1.12x | $572.41 Million |
| Zhejiang Jolly Pharmaceutical Co Ltd (300181) | $149.11 Million | 11.16% | 0.88x | $1.11 Billion |